An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Phase 1

Recruiting

• Conditions: Lung Adenocarcinoma
• Interventions: Drug: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside; Procedure: Computed Tomography; Other: Laboratory Biomarker Analysis; Procedure: Positron Emission Tomography

• Registration Number: NCT05558904
• Lead Sponsor: Jonsson Comprehensive Cancer Center

Brief Summary

The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.

Detailed Description

PRIMARY OBJECTIVE:

I. Assess the safety and efficacy of alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me-4FDG) for early diagnosis of lung cancer.

SECONDARY OBJECTIVE:

I. Evaluate the correlation of Me-4FDG positivity with histopathological features of the disease (tumor grade, expression of sodium-glucose cotransporter-2 inhibitors.(SGLT2).

OUTLINE:

Patients receive Me-4FDG tracer intravenously (IV) and then undergo PET/CT over 15 minutes.

After completion of study , patients are followed up at 7 days.

Study Timeline

• Study First Submitted: 2022-09-12
• Study First Submitted QC: 2022-09-23
• Study First Posted: 2022-09-28
• Study Start: 2023-01-19
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-21
• Last Update Posted: 2025-02-24
• Primary Completion: 2025-10-01
• Study Completion: 2026-10-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Age > 18 years
• Lung nodule >= 1 cm visualized by CT imaging
• CANCER ARM: Pathologically confirmed lung adenocarcinoma. For patients who are surgical candidates, the pathologic report on the surgical specimen will confirm the diagnosis. For patients who are not surgical candidates, the enrollment will be contingent upon a pathologic diagnosis of lung cancer obtained by needle biopsy
• BENIGN ARM: Lung nodules considered to be clinically benign, according to the Guidelines for Management of Incidental Pulmonary Nodules from the Fleischner Society. Will consider "benign" the nodules with a lung-RADS score of 1-3

Exclusion Criteria

• Pregnancy
• Diagnosis of diabetes
• Current treatment with SGLT2 inhibitors or metformin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Diagnostic (Me-4FDG PET/CT)	Laboratory Biomarker Analysis	Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
Diagnostic (Me-4FDG PET/CT)	Positron Emission Tomography	Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
Diagnostic (Me-4FDG PET/CT)	Computed Tomography	Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
Diagnostic (Me-4FDG PET/CT)	Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside	Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.

Primary Outcome Measures

Name	Time	Method
Specificity of Me-4FDG for lung cancer	within one week of experimental PET/CT scan	Will be estimated by the percentage of Me-4FDG negativity in lung nodules that have been determined radiologically and/or clinically to be benign with a lung-RAD (Lung Imaging Reporting and Data System), score 1-3.
Efficacy of Me-4FDG in diagnosing lung cancer	within one week of the experimental PET/CT scan	Will be evaluated by measuring the percentage of test positivity in patients with a pathological diagnosis of lung cancer.
Incidence of adverse events of Me-4FDG	From baseline to one week after Me-4FDG administration	Will tabulate the number of adverse events (AEs) and the severity of adverse events (SAEs) for the overall population as well as within subjects.
Sensitivity of Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me-4FDG) positron-emission tomography (PET) scans	within one month of surgery or biopsy	Will be determined by calculating the standardized uptake value (SUV) in the lesions and the contrast to noise ratio (CNR) relative to an area of normal lung surrounding the lesion, and evaluated by assessing the percentage of patients with a pathologic diagnosis of lung cancer that results positive at Me-4FDG PET scans.
Optimal combination of sensitivity and specificity	within one week of experimental PET/CT scan	Will combine SUV and CNR cut-points that yield the optimal combination of sensitivity (positivity within the adenocarcinoma group) and specificity (negativity with the benign group). Optimality will be based on the cut-points that maximize the Youden index (sum of the sensitivity plus specificity). Based on the combined cut point, will construct 95% confidence intervals for the sensitivity and specificity.

Secondary Outcome Measures

Name	Time	Method
Correlation of Me-4FDG positivity with histopathological features (tumor grade)	within one month of surgery or biopsy	Ordinal logistic regression will be used to assess the correlation between Me-4FDG uptake and tumor grade.
Correlation of Me-4FDG positivity with histopathological features (expression of SGLT2)	within two months of surgery or biopsy	Will be evaluated experimentally with validated specific antibodies.

Trial Locations

Locations (1)

Yesenia Calzada; 🇺🇸 Los Angeles, California, United States